Being involved in the customer’s drug development process from an early stage, Stevanato Group can deliver science-based innovation through various services, including:
Clinical, laboratory and registration services with its laboratory and Technology Excellence Center, such as the one to be opened in Boston, Massachusetts in 2020
High-quality product development, including in-depth risk analysis to ensure a standardized project execution process
Definition of new proof of concept with rapid prototyping and engineering especially for the optimization of customer’s filling process, automation and robotics in device assembly, testing and inspection
Advanced technical customer support benefiting from experts in the field of materials science (such as glass, plastics, polymers, coating, rubbers, and proteins), chemical science, mechanical engineering and medical devices
Generation of technical and regulatory documentation fully compliant with global regulations such as those of the US FDA, China FDA, and EMA
- Global growth of biologics (~10% CAGR 2013-18) has been higher vs. small molecules (~5% CAGR)
- More than 1/3 of drugs launched in the next 5 years will be brought to market by emerging biopharma companies
Regulators throughout the world are putting increased focus on safety and controls
Need to reduce drug development timeline, while maintaining drug integrity
CDx leverage biomarkers to predict the likely response of a drug to a specific patient
Increasing trend of self-medication to improve patient's adherence to therapy and reduce hospitalization costs
Rising healthcare costs are putting pressure on drug prices and reimbursement mechanisms